MX2007000360A - Marcadores moleculares de pronostico. - Google Patents

Marcadores moleculares de pronostico.

Info

Publication number
MX2007000360A
MX2007000360A MX2007000360A MX2007000360A MX2007000360A MX 2007000360 A MX2007000360 A MX 2007000360A MX 2007000360 A MX2007000360 A MX 2007000360A MX 2007000360 A MX2007000360 A MX 2007000360A MX 2007000360 A MX2007000360 A MX 2007000360A
Authority
MX
Mexico
Prior art keywords
patients
ecteinascidin
brca1
cancer
treatment
Prior art date
Application number
MX2007000360A
Other languages
English (en)
Inventor
Rafael Rosell Costa
Miguel Taron Roca
Jose Ma Jimeno Donaque
Juan Carlos Tercero Lopez
Original Assignee
Pharma Mar Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa
Publication of MX2007000360A publication Critical patent/MX2007000360A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La presente invencion se relaciona al uso de ceteinascidin 743 en pacientes que tienen ciertos niveles de marcadores moleculares, quienes pueden predecir el efecto de la quimioterapia, en particular en pacientes que tienen bajos niveles de expresion BRCA1.
MX2007000360A 2004-07-09 2005-07-11 Marcadores moleculares de pronostico. MX2007000360A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04076997 2004-07-09
PCT/EP2005/007605 WO2006005602A2 (en) 2004-07-09 2005-07-11 Use of ecteinascidin in the treatment of cancer in patients with low level of brca1

Publications (1)

Publication Number Publication Date
MX2007000360A true MX2007000360A (es) 2007-06-12

Family

ID=35478393

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007000360A MX2007000360A (es) 2004-07-09 2005-07-11 Marcadores moleculares de pronostico.

Country Status (8)

Country Link
US (1) US20080293725A1 (es)
EP (1) EP1768671A2 (es)
JP (1) JP2008505862A (es)
AU (1) AU2005261860A1 (es)
CA (1) CA2573072A1 (es)
MX (1) MX2007000360A (es)
NZ (1) NZ552607A (es)
WO (1) WO2006005602A2 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164077A (en) * 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
CA2428160C (en) * 2000-11-06 2009-10-13 Pharma Mar, S.A. Compositions for antitumor treatment containing ecteinascidin 743
GB0117402D0 (en) * 2001-07-17 2001-09-05 Pharma Mar Sa New antitumoral derivatives of et-743
US20080255132A1 (en) * 2003-11-14 2008-10-16 Eric Rowinsky Combination Therapy Comprising the Use of Et-743 and Paclitaxel for Treating Cancer
PL1827500T3 (pl) * 2004-10-26 2009-09-30 Pharma Mar Sa Pegylowana liposomalna doksorubicyna w kombinacji z ekteinascydyną 743
ES2290844T3 (es) 2004-10-29 2008-02-16 Pharma Mar S.A., Sociedad Unipersonal Composiciones que comprenden ecteinascidinas y un disacarido.
GB0522082D0 (en) * 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
AU2008313634A1 (en) * 2007-10-19 2009-04-23 Pharma Mar, S.A. Prognostic molecular markers for ET-743 treatment
EP2093566A1 (en) * 2008-02-21 2009-08-26 Pangaea Biotech, S.A. Method for the prognosis of non-small cell lung cancer
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089273A (en) * 1986-06-09 1992-02-18 Board Of Trustees Of The University Of Illinois Ecteinascidins 729, 743, 745, 759A, 759B and 770
US5149804A (en) * 1990-11-30 1992-09-22 The Board Of Trustees Of The University Of Illinois Ecteinascidins 736 and 722
US5256663A (en) * 1986-06-09 1993-10-26 The Board Of Trustees Of The University Of Illinois Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith
DE3635711A1 (de) * 1986-10-21 1988-04-28 Knoll Ag 5-nitrobenzo(de)isochinolin-1,3-dione, ihre herstellung und verwendung
US5478932A (en) * 1993-12-02 1995-12-26 The Board Of Trustees Of The University Of Illinois Ecteinascidins
US20040059112A1 (en) * 1994-02-18 2004-03-25 Rinehart Kenneth L. Ecteinascidins
GB9508195D0 (en) * 1995-04-20 1995-06-07 Univ British Columbia Novel biologically active compounds and compositions,their use and derivation
US5908876A (en) * 1996-04-19 1999-06-01 Mitsui Chemicals, Inc. Optical resin composition comprising a thiourethane prepolymer and use thereof
US5721362A (en) * 1996-09-18 1998-02-24 President And Fellows Of Harvard College Process for producing ecteinascidin compounds
US5985876A (en) * 1997-04-15 1999-11-16 Univ Illinois Nucleophile substituted ecteinascidins and N-oxide ecteinascidins
BR9909488B1 (pt) * 1998-04-06 2011-02-08 ecteinascidinas semi-sintéticas e composição farmacêutica.
MY164077A (en) * 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
CA2418320A1 (en) * 2000-08-11 2002-02-21 City Of Hope The anti-neoplastic agent et-743 inhibits trans activation by sxr
CA2428160C (en) * 2000-11-06 2009-10-13 Pharma Mar, S.A. Compositions for antitumor treatment containing ecteinascidin 743
EP1360337A1 (en) * 2001-02-09 2003-11-12 The Regents Of The University Of California Ecteinascidin family compounds: compositions and methods
JP2005509650A (ja) * 2001-10-19 2005-04-14 ファルマ・マール・ソシエダード・アノニマ 癌治療における抗腫瘍化合物の改良した使用
US20040019027A1 (en) * 2002-04-12 2004-01-29 Barry Forman Method of treating cerebrotendinous xanthomatosis
GB0312407D0 (en) * 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
GB0324201D0 (en) * 2003-10-15 2003-11-19 Pharma Mar Sau Improved antitumoral combinations
GB0326486D0 (en) * 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
ES2290844T3 (es) * 2004-10-29 2008-02-16 Pharma Mar S.A., Sociedad Unipersonal Composiciones que comprenden ecteinascidinas y un disacarido.

Also Published As

Publication number Publication date
AU2005261860A1 (en) 2006-01-19
US20080293725A1 (en) 2008-11-27
WO2006005602A3 (en) 2006-04-13
EP1768671A2 (en) 2007-04-04
NZ552607A (en) 2009-07-31
CA2573072A1 (en) 2006-01-19
WO2006005602A2 (en) 2006-01-19
JP2008505862A (ja) 2008-02-28

Similar Documents

Publication Publication Date Title
MX2007000360A (es) Marcadores moleculares de pronostico.
MX2007002398A (es) Nuevas composiciones farmaceuticas para el tratamiento de cancer.
SI1742644T1 (sl) Terapevtski sestavek ki vsebuje vsaj en derivat pirolobenzodiazepina in fludarabin
SG164368A1 (en) Treatment of cancer
MX361467B (es) Compuestos de isoindolina para uso en el tratamiento de cancer.
PT1984357E (pt) Compostos de 2,4-pirimidinadiamina para tratamento ou prevenção de doenças autoimunes
WO2006073457A8 (en) Bioactive compounds and methods of uses thereof
DK1853250T3 (da) Kombinationer og måder til indgivelse af terapeutiske midler og kombinationsterapi
MY165570A (en) Inhibitors of poly (adp-ribose) polymerase
MX349188B (es) Sns - 595 y metodos para utilizar el mismo.
TW200612918A (en) Lonidamine analogs
TW200621736A (en) Mitotic kinesin inhibitors and methods of use thereof
UA89226C2 (en) Imidazole compounds
UA91676C2 (ru) Композиция, которая содержит ингибитор jnk и циклоспорин
TW200509892A (en) Novel aminobenzophenone compounds
TW200642682A (en) A combination of medical drugs to augment the anti-cancer effect of chemotherapy
WO2007101235A3 (en) Improved antitumoral treatments
TW200640893A (en) Cytotoxic agents comprising new C-2 modified taxanes
MX2008015775A (es) Compuestos y composiciones para tratamiento de cancer.
NO20055563L (no) Midler for behandlingen av lavere abdominale lidelser
ZA200801332B (en) Pentacyclic kinase inhibitors
GB0416508D0 (en) Therapeutic agents
WO2007130501A3 (en) Combination therapy for treatment of cancer
SI1838716T1 (sl) Olanzapin pamoat dihidrat
MX2009001433A (es) Nucleosidos para suprimir o reducir el desarrollo de resistencia en terapia citostatica.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal